Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 12Carcinoma, Hepatocellular 11Carcinoma, Non-Small-Cell Lung 9Nasopharyngeal Carcinoma 8Esophageal Squamous Cell Carcinoma 8Stomach Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Colorectal Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Small Cell Lung Carcinoma 4Liver Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Sarcoma 3Neoplasm Metastasis 3Lung Neoplasms 3Hypopharyngeal Neoplasms 3Cholangiocarcinoma 3Solid Tumor 2Recurrence 2Lymphoma 2Laryngeal Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Advanced Solid Tumor 2Upper Tract Urinary Carcinoma 1Thyroid Neoplasms 1Thymic epithelial tumor 1

Interventions

HMPL-013 2toripalimab 1tislelizumab 1sintilimab 1regorafenib 1raltitrexed 1pembrolizumab 1camrelizumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Colorectal Carcinoma × toripalimab × Clear all
NCT04771715 2021-02-25

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Peking Union Medical College Hospital

Unknown
100 enrolled
Gastrointestinal

Advanced Colorectal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡